Not exactly a surprise to informed investors, but nice to read a...

Not exactly a surprise to informed investors, but nice to read a company being so open about it:

"Opthea believes that its existing cash and cash equivalents as of June 30, 2023, as well as net proceeds from the 2023 Equity Offering, – and the incremental US$50 million under the funding agreement as described above is received, and the remaining $35 million under the Funding Agreement which is expected to be received by December 31, 2023, if received, will enable us to fund our operating and research and development expenses into the third calendar quarter of 2024. If patient enrollment continues to be delayed in the future, or if any additional factors cause the Phase 3 clinical trials to be further delayed or more costly, then Opthea will need to obtain additional financing earlier than the third quarter of calendar year 2024. However, Opthea will need to raise additional funds to complete the efficacy and safety phase of both studies and to report top-line data."